
Albert AntolÃ-n Santaliestra

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3178127/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Identification of different side effects between PARP inhibitors and their polypharmacological multiâ€ŧarget rationale. British Journal of Clinical Pharmacology, 2022, 88, 742-752.	1.1	38
2	Rare Variation in Drug Metabolism and Long QT Genes and the Genetic Susceptibility to Acquired Long QT Syndrome. Circulation Genomic and Precision Medicine, 2022, 15, CIRCGEN121003391.	1.6	7
3	canSAR chemistry registration and standardization pipeline. Journal of Cheminformatics, 2022, 14, .	2.8	5
4	canSAR: update to the cancer translational research and drug discovery knowledgebase. Nucleic Acids Research, 2021, 49, D1074-D1082.	6.5	63
5	Public resources for chemical probes: the journey so far and the road ahead. Future Medicinal Chemistry, 2021, 13, 731-747.	1.1	24
6	Evolution of kinase polypharmacology across HSP90 drug discovery. Cell Chemical Biology, 2021, 28, 1433-1445.e3.	2.5	13
7	Al delivers Michaelis constants as fuel for genome-scale metabolic models. PLoS Biology, 2021, 19, e3001415.	2.6	3
8	The kinase polypharmacology landscape of clinical PARP inhibitors. Scientific Reports, 2020, 10, 2585.	1.6	68
9	Transforming cancer drug discovery with Big Data and Al. Expert Opinion on Drug Discovery, 2019, 14, 1089-1095.	2.5	22
10	Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen. Nature Communications, 2019, 10, 2674.	5.8	240
11	canSAR: update to the cancer translational research and drug discovery knowledgebase. Nucleic Acids Research, 2019, 47, D917-D922.	6.5	75
12	Abstract LB-C01: The kinase polypharmacology landscape of clinical PARP inhibitors. , 2019, , .		0
13	Objective, Quantitative, Data-Driven Assessment of Chemical Probes. Cell Chemical Biology, 2018, 25, 194-205.e5.	2.5	71
14	Dual Inhibitors of PARPs and ROCKs. ACS Omega, 2018, 3, 12707-12712.	1.6	5
15	Polypharmacology in Precision Oncology: Current Applications and Future Prospects. Current Pharmaceutical Design, 2017, 22, 6935-6945.	0.9	65
16	canSAR: an updated cancer research and drug discovery knowledgebase. Nucleic Acids Research, 2016, 44, D938-D943.	6.5	114
17	Distant Polypharmacology among MLP Chemical Probes. ACS Chemical Biology, 2015, 10, 395-400.	1.6	28
18	In Silico Prescription of Anticancer Drugs to Cohorts of 28 Tumor Types Reveals Targeting Opportunities. Cancer Cell, 2015, 27, 382-396.	7.7	290

#	Article	IF	CITATIONS
19	Abstract 2983: In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals novel targeting opportunities. , 2015, , .		3
20	Linking off-target kinase pharmacology to the differential cellular effects observed among PARP inhibitors. Oncotarget, 2014, 5, 3023-3028.	0.8	49
21	Exploring the effect of PARP-1 flexibility in docking studies. Journal of Molecular Graphics and Modelling, 2013, 45, 192-201.	1.3	16
22	Identification of Pim Kinases as Novel Targets for PJ34 with Confounding Effects in PARP Biology. ACS Chemical Biology, 2012, 7, 1962-1967.	1.6	65